Published 2026-08-04
Summary: Smith & Nephew cut its full-year revenue-growth forecast after weaker demand for hip and knee implants in the United States, citing ongoing weakness in its orthopaedics unit in the U.S., its largest market. The company now expects revenue growth around the mid-single digits for the year, with the precise percentage not specified in available information.
What We Know
- Smith & Nephew reduced its revenue-growth forecast for the year due to weaker demand for hip and knee implants in the U.S.
- The full-year revenue growth forecast was lowered to around 4% according to reporting, with notes that this is a rough figure extracted from available summaries.
- Continued weakness in Smith & Nephew’s orthopaedics unit in the U.S., its largest market, weighed on expectations for full-year revenue.
- First-quarter results indicated revenue broadly in line with analyst expectations despite a sharp decline in the U.S. knee implant segment.
- The news is tied to ongoing challenges in the U.S. market for orthopaedic implants affecting overall growth outlook.
What’s Still Unclear
- The exact revised percentage for the revenue growth forecast beyond around 4% is not stated in the available information.
- The specific magnitude or percentage decline in the U.S. knee implant segment is not provided here.
- Whether other product segments are offsetting the US orthopaedics weakness remains unspecified.
Context
Smith & Nephew operates across medical devices with a notable focus on orthopaedics in the United States. Weakness in demand for hip and knee implants can influence overall revenue growth projections, particularly when the U.S. market is its largest. Market responses to pricing, competition, and recovery in elective procedures can impact quarterly and full-year outlooks for such companies.
Why It Matters
The revision of the revenue-growth forecast signalshed investors and analysts that demand conditions in the U.S. orthopaedics market remain challenging, which can affect investor sentiment, funding for product launches, and strategic priorities in the near term.
What to Watch Next
- Any updates on quarterly earnings guidance or next-quarter revenue expectations.
- Company commentary on initiatives to revive demand in the U.S. hip and knee implant segments.
- Progress or results from new knee implant launches or other product initiatives.
- Competitor performance and market share shifts in the U.S. orthopaedics space.
FAQ
Q: What caused Smith & Nephew to lower its forecast?
A: Weighing on the outlook is ongoing weakness in the U.S. orthopaedics unit, particularly for hip and knee implants.
Q: Is the revised forecast a precise percentage?
A: The approximate figure mentioned is around 4%, but the exact revised percentage is not explicitly stated in the available information.
Related coverage
- Lufthansa fuel price volatility uncertainty Threatens 2024
- Australia consumer demand resilience rises as households
- RBI rate decision outlook: Seen holding rates amid
Source Transparency
- This article is based on a short preliminary brief and may not reflect the full details available in ongoing reporting.
- Source links are provided in the Sources section where available.
- A limited open-web check was used to clarify key details when possible; unclear items remain clearly marked.
Original brief: Smith & Nephew cut its revenue-growth forecast for the year after weaker demand for hip and knee implants in the US…
Sources
- Smith & Nephew Sees Slower Sales Growth on Weak Implants Demand
- UK's Smith+Nephew cuts annual revenue expectations on US orthopaedic …
- Smith & Nephew Q1: CEO Bets On LANDMARK Knee Launch To Reverse Double …
- Smith & Nephew (SN.) shares fall after weakness in US knee implant business
- Smith & Nephew shares dip on weak US knee implant sales